Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Financing Activities (2016 - 2025)

Sunshine Biopharma's Cash from Financing Activities history spans 14 years, with the latest figure at $724500.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 55.23% year-over-year to $724500.0; the TTM value through Dec 2025 reached $4.7 million, down 46.9%, while the annual FY2025 figure was $4.7 million, 46.9% down from the prior year.
  • Cash from Financing Activities reached $724500.0 in Q4 2025 per SBFM's latest filing, up from $75536.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $29.1 million in Q2 2022 to a low of -$2.1 million in Q4 2022.
  • Average Cash from Financing Activities over 5 years is $3.1 million, with a median of $724500.0 recorded in 2025.
  • Peak YoY movement for Cash from Financing Activities: plummeted 8758.42% in 2022, then soared 12730.71% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$23664.0 in 2021, then tumbled by 8758.42% to -$2.1 million in 2022, then skyrocketed by 98.54% to -$30519.0 in 2023, then skyrocketed by 5402.28% to $1.6 million in 2024, then plummeted by 55.23% to $724500.0 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Cash from Financing Activities are $724500.0 (Q4 2025), $75536.0 (Q3 2025), and $3.6 million (Q2 2025).